CAMPATH-1 MONOCLONAL-ANTIBODY THERAPY IN SEVERE REFRACTORY AUTOIMMUNE THROMBOCYTOPENIC PURPURA

被引：42

作者：

LIM, SH ^{[1
]}

HALE, G ^{[1
]}

MARCUS, RE ^{[1
]}

WALDMANN, H ^{[1
]}

BAGLIN, TP ^{[1
]}

机构：

[1] UNIV CAMBRIDGE,DEPT PATHOL,DIV IMMUNOL,CAMBRIDGE,ENGLAND

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 1993年 / 84卷 / 03期

基金：

英国惠康基金;

关键词：

D O I：

10.1111/j.1365-2141.1993.tb03117.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Six patients with autoimmune thrombocytopenic purpura (three of whom had CLL/NHL and one previous Hodgkin's disease) refractory to conventional therapy were treated with an antilymphocyte monoclonal antibody directed at CDw52 (CAMPATH-1). We observed response in four of the five evaluable patients; in three patients the response has lasted more than 4-9 months. However. response did not occur in most cases until 4-6 weeks after the commencement of the antibody therapy, suggesting that the mechanism of action is probably that of immune modulation.

引用

页码：542 / 544

页数：3